Acalabrutinib


Acalabrutinib is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically it is for people who had previously been treated with another therapy. As of 2019, it was unclear whether it improved outcomes.
Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. It is a second generation Bruton's tyrosine kinase inhibitor.
Acalabrutinib was approved for medical use in the United States in 2017. The wholesale cost as of 2018 in the United States is US$14,064 per month.

Medical uses

It is used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. It is unclear if it results in improved outcomes as of 2019.

Side effects

The most common adverse events were headache, diarrhea and weight gain. Despite the appearance of a greater occurrence of transient headaches, data suggests a preferred advantage of acalabrutinib over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.

Society and culture

Names

Acalabrutinib is the INN.

Regulatory

As of February 2016, acalabrutinib had received orphan drug designation in the United States for mantle cell lymphoma and chronic lymphocytic leukemia,
and was similarly designated as an orphan medicinal product by the European Medicines Agency Committee for Orphan Medicinal Products for treatment of three indications - CLL/ small lymphocytic lymphoma, mantle cell lymphoma, and lymphoplasmacytic lymphoma. Approval would result in a 10-year period of market exclusivity for the stated indications within Europe.

Economics

It was developed by Acerta Pharma. After promising results for CLL in initial clinical trials, Astra Zeneca purchased a 55% stake in Acerta Pharma for $4 billion in December 2015, with an option to acquire the remaining 45% stake for an additional $3 billion, conditional on approval in both the US and Europe and the establishment of commercial opportunity.

Research

Relative to ibrutinib, acalabrutinib demonstrated higher selectivity and inhibition of the targeted activity of BTK, while having a much greater IC50 or otherwise virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In addition, in platelets treated with ibrutinib, thrombus formation was clearly inhibited while no impact to thrombus formation was identified relative to controls for those treated with acalabrutinib. These findings strongly suggest an improved safety profile of acalabrutinib with minimized adverse effects relative to ibrutinib. In pre-clinical studies, it was shown to be more potent and selective than ibrutinib, the first-in-class BTK inhibitor.
The interim results of the still on-going first human phase 1/2 clinical trial with 61 patients for the treatment of relapsed chronic lymphocytic leukemia are encouraging, with a 95% overall response rate demonstrating potential to become a best-in-class treatment for CLL. Notably, a 100% response rate was achieved for those people which were positive for the 17p13.1 gene deletion - a subgroup that typically results in a poor response to therapy and expected outcomes.